Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq data of primary human hepatocytes spheroids treated with AZD1979

ABSTRACT: Primary human hepatocytes from 3 different donors as 3D spheroids treated with AZD1979 (5 concentrations) and vehicle for 7 h. Data for Figure 4 in connected publication.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: John Hellgren

PROVIDER: E-MTAB-15609 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq data of primary human hepatocytes spheroids treated with compounds (experiment 2)

Project description:Primary human hepatocytes from 3 different donors as 3D spheroids treated with 8 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 1 in connected publication. Experiment 2 of 2.

2026-01-16 | E-MTAB-15587 | biostudies-arrayexpress

RNA-seq data of primary human hepatocytes spheroids from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) donors following troglitazone treatment

Project description:Primary human hepatocytes from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) patients (6 donors each) as 3D spheroids treated with troglitazone (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Data for Figure 5 in connected publication.

2026-01-16 | E-MTAB-15610 | biostudies-arrayexpress

RNA-seq data of primary human hepatocytes spheroids treated with compounds (experiment 1)

Project description:Primary human hepatocytes from 3 different donors as 3D spheroids treated with 14 compounds (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Compounds have different degree of drug-induced liver injury concern. Data for Figure 1 in connected publication. Experiment 1 of 2.

2026-01-16 | E-MTAB-15586 | biostudies-arrayexpress

RNA-Seq of A549 cells treated with chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined 37 mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2023-12-20 | E-MTAB-12574 | biostudies-arrayexpress

RNA-Seq of chemical modification patterns for microRNA therapeutic mimics, a case-study on miR-200c, miR-155 and miR34a

Project description:We examined the influence of chemical modifications patterns in a set of miR-200c, miR-155 and miR-34a mimics, assessing the regulation of the whole transcriptome in A549 cells. We examined the mimics and provided an initial set of rules for designing miRNA mimics with potency and selectivity similar to an unmodified miRNA duplex.

2024-02-15 | E-MTAB-13801 | biostudies-arrayexpress

Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis

Project description:Hepatocellular carcinoma (HCC) is frequently characterized by metabolic and immune remodeling in the tumor microenvironment. We previously discovered that liver-specific deletion of fructose-1, 6-bisphphotase 1 (FBP1), a gluconeogenic enzyme ubiquitously suppressed in HCC tissues, promotes liver tumorigenesis, and induces metabolic and immune perturbations closely resembling human HCC. However, the underlying mechanisms remain incompletely understood. Here we reported that FBP1-deficient livers exhibit diminished amounts of natural killer (NK) cells and accelerated tumorigenesis. Using the diethylnitrosamine-induced HCC mouse model, we analyzed potential changes in the immune cell populations purified from control and FBP1-depleted livers and found that NK cells were strongly suppressed. Mechanistically, FBP1 attenuation in hepatocytes derepresses an EZH2-dependent transcriptional program to inhibit PKLR expression. This leads to reduced levels of PKLR cargo proteins sorted into hepatocyte-derived EVs, dampened activity of EV-targeted NK cells, and accelerated liver tumorigenesis. Our study demonstrated that hepatic FBP1 depletion promotes HCC-associated immune remodeling, partly through the transfer of hepatocyte-secreted, PKLR-attenuated EVs to NK cells.

2023-03-11 | PXD026822 | Pride

YBEY is an essential biogenesis factor for mitochondrial ribosomes

Project description:The aim was to evaluate the protein composition of human mitoribosomes in YBEY knockout cells. We compared the parental cell line HEK293T-REx with the YBEY knockout cells HEK293T-RExΔYBEY.

2020-03-02 | PXD015310 | Pride

RASSF1C oncogene elicits amoeboid invasion, cancer stemness and invasive EVs via a novel SRC/Rho axis

Project description:Cell plasticity is a crucial hallmark leading to cancer metastasis. Upregulation of Rho/ROCK pathway drives actomyosin contractility, protrusive forces and contributes to the occurrence of highly invasive amoeboid cells in tumors. Cancer stem cells are similarly associated with metastasis, but how these populations arise in tumors is not fully understood. Here we show that the novel oncogene RASSF1C drives mesenchymal to amoeboid transition and stem cell attributes in breast cancer cells. Mechanistically, RASSF1C activates Rho/ROCK via SRC mediated RhoGDI inhibition, resulting in generation of actomyosin contractility. Moreover, we demonstrate that amoeboid cells display the cancer stem cell markers CD133, ALDH1 and the pluripotent marker Nanog; are accompanied by higher invasive potential in vitro and in vivo; and employ extracellular vesicles to transfer the invasive phenotype to target cells and tissue. Importantly, the underlying RASSF1C driven biological processes concur to explain clinical data: namely, methylation of the RASSF1C promoter correlates with better survival in early stage breast cancer patients. Therefore, we propose the use of RASSF1 gene promoter methylation status as a biomarker for patient stratification.

2021-10-07 | PXD026226 | Pride

Soybean leaf cytosolic proteome analysis by CFMS

Project description:Soybean leaf cytosolic proteome was fractionized by SEC and analyzed by LC-MSMS.

2021-06-17 | PXD021452 | Pride

Akkermansia muciniphila SEV-containing proteins smaller than 30 kDa

Project description:Histone lysine lactylation (Klac) is a new posttranslational modification (PTM) that is installed by acetyltransferase to modulate specific immune responses1 and oncogenesis2,3. Akkermansia muciniphila (A. muciniphila) is a beneficial bacterium that blunts ulcerative colitis (UC) in a mouse model by secreting extracellular vesicles (SEVs)4. Although many histone sites are known to contain lysine lactylation, whether this modification is regulated to modulate specific biological functions by exogenous acetyltransferase or intestinal microbiota is not well understood. Here, we discovered that SEV from A. muciniphila, rather than A. muciniphila per se, has anti-Th17 (T helper 17) differentiation activity. We further screened the composition of SEV and found that Amuc_2172 is the key active component. As a GCN5-related acetyltransferase of A. muciniphila, Amuc_2172 is accessible to naïve T cells and functions as a lactylation transferase on Lys4 of histone H3. Accelerated histone H3 lactylation (H3Klac) on Lys4 competitively blocks trimethylation (H3Kme3) on Il17a loci in the process of Th17-cell differentiation. Additionally, intraperitoneal application of recombinant Amuc_2172 also inhibited Th17 and dextran sulfate sodium (DSS)-induced UC phenotypes in vivo; moreover, bioengineered Amuc_2172 showed improved colitis site delivery and higher Th17 inhibition potential compared to Amuc_2172 alone. Our study reveals not only a potential therapeutic strategy for treating colitis but also a model via which lysine lactylation is regulated by the intestinal microbiota, which may be broadly applicable to understand the crosstalk of bacteria and immunity.

2023-11-28 | PXD037100 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data